Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...
-
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...
-
Oslo, Norway, November 6, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that data will be...
-
Novel treatment for moderate to severe acne Oslo, Norway, October 30, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and...
-
Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third...
-
Photocure will present its third quarter 2013 report on Wednesday 23 October 2013 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company...
-
The annual report for Photocure ASA (the "Company") for 2012 has previously been made available at the Company's web page: http://www.photocure.com/Investor-relations/, and is now also published on...
-
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...
-
Oslo, Norway, 22 August 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the...
-
Photocure will present its second quarter and first half 2013 report on Thursday 22 August 2013 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...